Full history for every metric is available with a Kvantra account
Organovo Holdings, Inc. (ONVO)
Key financial summary
Financials in USD| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -11 | -11 | |||||
| Net profit | $m | -17 | -11 | -17 | -15 | -2 | -14 | -12 |
| EPS reported | $ | -5.35 | -4.46 | |||||
| Operating cashflow per share | $ | -4.42 | -3.57 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -4.42 | -3.57 | |||||
| Free cash flow | $m | -11 | -19 | |||||
| Net debt | $m | -5 | -2 | |||||
| Book value equity | $m | -1 | -2 | |||||
| Book value per share | $ | -0.42 | -0.45 | |||||
| Number of shares | m | 2.59 | 5.24 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -4.80 | -1.57 | |||||
| P/S LTM | x | 40.31 | 32.79 | |||||
| P/FCF LTM | x | -0.46 | -0.20 | |||||
| EV/EBITDA LTM | x | -0.06 | -0.17 | |||||
| EV/Sales LTM | x | 5.37 | 17.88 | |||||
| Earnings Yield LTM | % | -262.17% | -115.43% | |||||
| FCF Yield | % | -216.89% | -509.59% | |||||
| Quality | ||||||||
| ROE | % | 1259.6% | -612.23% | |||||
| ROIC | % | -227.52% | -498.96% | |||||
| Operating margin | % | -8768.7% | -10117.0% | |||||
| Gross margin | % | 100.00% | 116.96% | |||||
| FCF/Sales | % | -8742.0% | -16707.1% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -9.03% | -21.13% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -25.62 | -59.22 | |||||
| Net Debt/EBITDA | x | 0.40 | 0.12 | |||||
| EBIT/Net interest | x | 957.25 | 566.55 | |||||
| Net debt/market cap | % | -86.68% | -45.48% | |||||
| Net debt/Equity | x | 4.16 | 0.71 | |||||
| Gross debt/equity | x | -0.41 | -0.13 | |||||
Company overview
Organovo Holdings, Inc. is a biotechnology firm that specializes in engineering sophisticated 3D tissues designed to accurately mimic critical facets of human diseases. Central to its operations is a comprehensive 3D human tissue platform, which features the company's proprietary NovoGen Bioprinters. These automated devices are crucial for fabricating complex, living 3D tissues from mammalian cells. The platform also includes supporting technologies necessary for creating specialized "bio-inks" and for the bioprinting of multi-cellular tissues with intricate structures. Organovo supplies specific products, such as ExVive human liver tissue and ExVive human kidney tissue, which are employed for predictive preclinical evaluation of investigational drug compounds. The company was founded in 2007 and maintains its corporate headquarters in Solana Beach, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Organovo Holdings, Inc. (ONVO)
Organovo Holdings, Inc. is a biotechnology firm that specializes in engineering sophisticated 3D tissues designed to accurately mimic critical facets of human diseases. Central to its operations is a comprehensive 3D human tissue platform, which features the company's proprietary NovoGen Bioprinters. These automated devices are crucial for fabricating complex, living 3D tissues from mammalian cells. The platform also includes supporting technologies necessary for creating specialized "bio-inks" and for the bioprinting of multi-cellular tissues with intricate structures. Organovo supplies specific products, such as ExVive human liver tissue and ExVive human kidney tissue, which are employed for predictive preclinical evaluation of investigational drug compounds. The company was founded in 2007 and maintains its corporate headquarters in Solana Beach, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free